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Do mammals make all their own inositol hexakisphosphate?
Andrew J. LETCHER, Michael J. SCHELL1 and Robin F. IRVINE2
Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.
A highly speciﬁc and sensitive mass assay for inositol hexakis-
phosphate (InsP6) was characterized. This centres around phos-
phorylatingInsP6 with[
32P]ATPusingarecombinantInsP6 kinase
from Giardia lambia, followed by HPLC of the
32P-labelled
products with an internal [
3H]InsP7 standard. This assay was
used to quantify InsP6 levels in a variety of biological samples.
Concentrations of InsP6 in rat tissues varied from 10–20 μM
(assuming64%ofwetweightoftissueiscytosolwater),whereas
using the same assumption axenic Dictyostelium discoideum
cells contained 352+ −11 μMI n s P6. HeLa cells were seeded at
low density and grown to conﬂuence, at which point they con-
tained InsP6 levels per mg of protein similar to rat tissues. This
amounted to 1.952+ −0.117 nmol InsP6 per culture dish, despite
the cells being grown in serum shown to contain no detect-
able (less than 20 pmol per dish) InsP6. Theseresults demonstrate
thatmammaliancellssynthesizealltheirownInsP6.Humanblood
was analysed, and although the white cell fraction contained
InsP6 at a concentration comparable with other tissues, in
serum and platelet-free plasma no InsP6 was detected (<1n M
InsP6). Human urine was also examined, and also contained
no detectable (<5n M )I n s P6. These results suggest that dietary
studiespurportingtomeasureInsP6 atmicromolarconcentrations
in human plasma or urine may not have been quantifying this
inositol phosphate. Therefore claims that administrating InsP6 in
the diet or applying it topically can produce health beneﬁts by
increasing extracellular InsP6 levels may require reassessment.
Key words: dietary phytate, inositol hexakisphosphate (InsP6),
mass assay, phytate, phytic acid.
INTRODUCTION
InsP6 was originally discovered as the major plant phosphate
storage compound [1,2], hence its alternative name, phytic acid.
It was generally assumed to be plant speciﬁc until the rekindled
interest in inositol phosphates that followed the discovery
of Ins(1,4,5)P3 as a second messenger [3] led to the realization
that InsP6 is also found in animal cells (e.g. [4,5] and see [6,7] for
reviews).
In the intervening years, the route by which animals synthesize
InsP6 was controversial [6], but further studies have led to a
likely consensus. Unlike slime moulds [8] and plants [9], which
can synthesize InsP6 by stepwise phosphorylation directly from
inositol, animals apparently incorporate the ﬁrst three phosphates
while the inositol is in its lipid form. That is, Ins(1,4,5)P3
is formed by phospholipase C action on PtdIns(4,5)P2,a n d
Ins(1,4,5)P3 is then phosphorylated up to InsP6. The synthesis
ofIns(1,3,4,5,6)P5 fromIns(1,4,5)P3 ismostlikelytobemediated
byatwo-step conversioncatalysedbyasingleenzyme,Ipk2(ino-
sitolpolyphosphatemultikinase)[10–12];thisenzymeisessential
for mammalian embryonic survival [13], though it is not certain
yetwhetherthatisbecauseofitsactivityinconvertingIns(1,4,5)P3
into Ins(1,3,4,5,6)P5. The alternative route from Ins(1,4,5)P3 to
Ins(1,3,4,5,6)P5 via Ins(1,3,4,5)P4, Ins(1,3,4)P3 and Ins-
(1,3,4,6)P4 isprobablyquantitativelyminor,atleastinﬁbroblasts,
as suggested by the results of Leyman et al. [14], who showed
that mouse embryonic ﬁbroblasts devoid of any Ins(1,4,5)P3
3-kinase isoforms synthesized InsP6 at a rate indistinguishable
from wild-type ﬁbroblasts; in contrast, ﬁbroblasts derived from
Ipk2 knockout mice show a greatly compromised InsP6 synthesis
[13]. The ﬁnal step of InsP6 synthesis (as in plants and slime
moulds [8,9]) is the 2-phosphorylation of Ins(1,3,4,5,6)P5 by
InsP5 2-kinase[11,15],anenzymewhichisalsoessentialtoviable
mammalian development [16].
However, although we now know that mammalian cells can
synthesize InsP6, how they probably do so, and that it is essential
thattheydosynthesizeInsP6,thecontributionofexogenousInsP6
to mammalian InsP6 homoeostasis is not so clear. A number of
studies have reported increases in InsP6 levels in tissue and body
ﬂuids resulting from the supply of exogenous InsP6 [17–20], and
other work has suggested that InsP6 added to cell cultures or
tissues can impinge on their physiology or pathology [21–23].
As a result of these and other studies there are many claims of
therapeutic or other beneﬁcial effects of InsP6 (e.g. [23,24] and
manyof theseare predicatedontheidea that exogenousInsP6 can
directly and signiﬁcantly inﬂuence both extra- and intracellular
InsP6 levels in the body.
In the present study, we have designed and characterized an
unambiguous mass assay for InsP6.T h i sa s s a yi sm o r et i m e -
consuming and complex than others (e.g. [18,25]), but its parti-
cular strength is a very high sensitivity and applicability to most
sample types. Our results provide some new insights into InsP6
levels in a number of tissues and address whether mammalian
cells can make all their own InsP6. Our results also cast doubts
on the idea that InsP6 is directly taken up into human tissues and
cells.
EXPERIMENTAL
Reagents
All chemicals and biochemicals used were of AnalaR grade
unless speciﬁed otherwise. [
3H]InsP6 was from PerkinElmer.
A[
3H]InsP7 standard (probably 5-[PP]InsP5, see the Results
Abbreviations used: d.p.m., disintegrations per min; Ipk2, inositol polyphosphate multikinase; TCA, trichloroacetic acid.
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section) was prepared by incubating [
3H]InsP6 with Giardia
lambia InsP6 kinase under the normal assay conditions (see
below for details) such that approx. 50% of the InsP6 was
phosphorylated.ThecorrectnomenclaturefortheproductofInsP6
phosphorylation by InsP6 kinase is [PP]InsP5, and we have used
this nomenclature when necessary for unambiguity (e.g. when
specifying isomers). However, for most of the present paper
we have used InsP7 as a simpler alternative. Sources of InsP5
isomers and scyllo-inositol hexakisphosphate were as described
previously [26].
InsP6 kinase
This is a recombinant enzyme from G. lambia. The sequence of
Giardia InsP6 kinase (Genbank® Nucleotide Sequence Database
accession number AY227443) was ampliﬁed from Giardia geno-
mic DNA (the gene contains no introns), and then cloned into the
hexahistidinebacterialvectorpET43A,whichfusesthesolubility-
enhancing bacterial protein NusA to the N-terminus of the fusion
protein. The enzyme was purifed by talon-bead absorption and
imidazole elution as described previously [27]. As discussed
previously [27], there is no obvious reason why a recombinant
mammalianInsP6 kinaseshouldnotbesubstitutedfortheGiardia
enzyme in this assay, although the high afﬁnity and speciﬁcity of
the Giardia InsP6 kinase (see the Results section) does make it
particularly suitable in this context.
Extraction protocol
For solid tissue samples, 20–50 mg of tissue was weighed before
homogenizing with a ground glass pestle in 180 μl of water. This
was rinsed with 70 μl of water and then transferred to a 1.5 ml
Eppendorftube,and50%(w/v)TCA(trichloroaceticacid)added
to give a ﬁnal concentration of 8.3% (v/v). After vortexing and
standing on ice for 30 min, samples were centrifuged at 13000 g
for 15min in a Microfuge, the supernatant was removed and
the pellet was kept for protein determination (see below). The
supernatant containing inositol phosphates was washed ten times
with water-saturated diethyletherto remove TCA[28]and ﬁnally
neutralized with 15 μl of 1:10 (v/v) saturated ammonia. Tubes
were spun in a centrifugal vacuum dryer for 5 min at 35◦Ca n d
thenfor30 minat45◦Ctoremovetheether,beforebeingadjusted
to 300 μl with water and the pH checked to ensure it was approx.
pH 6.0. For most assays, we took as an aliquot the equivalent of
1 mg of wet weight of starting tissue for the InsP6 assay.
InsP6 mass assay
Samples of tissue extract were incubated in a ﬁnal volume of
300 μl containing the following: 30 μlo f1 0 × assay buffer
[500 mM Hepes/NaOH (pH 7.5), 1 M KCl, 50 mM MgCl2,
10 mM EGTA and 5 mg/ml BSA], 6 μl of 600 μM 2-merc-
aptoethanol and 10 μlo f[ γ-
32P]ATP (10 μCi; PerkinElmer).
After 60 min incubation at 37◦C, 45 μl of 0.1 M glucose and 6 μl
of hexokinase (20 units, Sigma) were added, and the incubation
was continued at 37◦C for another 90 min to convert all the
remaining radioactivity into [
32P]glucose 6-phosphate.
The reaction was stopped by the addition of 0.5 ml of 0.4 M
ammonium formate/0.1 M formic acid, and the samples were
loadedonto0.5 mlofDowexFormateinaBioRadEconoColumn
(with a disc of Whatman Filter paper number 1 on top of the
Dowex resin) [29]. Samples were rinsed on to the column with
4 ml of 0.4 M ammonium formate/0.1 M formic acid, and the
column was washed with 10 ml of 0.8 M ammonium formate/
0.1 M formic acid to remove any remaining [
32P]glucose 6-phos-
phate.Thehigherinositolphosphateswereelutedwith2×1m lo f
2.5 M ammonium formate/0.1 M formic acid. They were spiked
with 600–2000 d.p.m. (disintegrations per min) of [
3H]InsP7 and
loaded on to a Whatman Patisil 10 SAX WCS analytical HPLC
column(4.6×250 mm,cataloguenumber4226-001)orasimilar-
sized column packed with the same material by Phenomenex.
HPLC
The column was eluted at 1 ml/min ﬂow rate with the following
programme:solutionA,waterandsolutionB,1.2 M(NH4)2HPO4
(pH 3.8) adjusted with phosphoric acid. The proﬁle gives the
percentage of solution B (v/v) added: 0 min, 0%;5m i n ,0 %;
30 min, 78%;7 5 m i n ,7 8 %; 76 min, 100%; 81 min, 100%;
82 min, 0%; 102 min, 0%.
Fractions (1 ml) were usually collected between 40 and 75 min
(InsP7 elutes at approx. 60 min) and were counted in a scin-
tillation counter after adding 10 ml of Ultima-Flo AP ammonium
phosphate-tolerantscintillation ﬂuid(PerkinElmer).The[
3H]and
[
32P] windows were calibrated using standards to ensure each
isotope was counted independently (spill over between channels
was <1%).
Protein assay
Pellets from the TCA tissue extracts were dissolved in 4 ml of
8 Mureabysonication(inaDeconultrasonicbath)andvortexing.
The majority of material dissolved, but in samples with a high fat
content some fat could remain in suspension and may interfere
with the assay (this did not happen in any sample analysed in
the present study). Samples were adjusted to a ﬁnal concentration
of 6 M urea, and assayed for protein using the Bio-Rad protein
assay, based on a method published previously by Bradford [30],
using BSA in 6 M urea as a protein standard.
Blood fractionation
Blood was taken from unfasted human volunteers who denied
having taken aspirin in the preceding 48 h, mixed with acid
citrate dextrose (97 mM sodium citrate, 78 mM citric acid and
110 mM D-glucose) and centrifuged at 200 g for 20 min (all
centrifugations were performed at 4◦C). The supernatant from
this centrifugation (platelet-rich plasma) was further centrifuged
at 2500 g for 20 min, and the resulting supernatant (platelet-
free plasma) was removed and frozen. The pellet from the ﬁrst
centrifugation was resuspended in 25 ml of resuspension buffer
[10 mM Hepes/NaOH (pH 7.4), 10 mM glucose, 1 mM MgSO4,
145 mM NaCl and 5 mM KCl], and then centrifuged (2500 g
for 20 min). The ‘buffy coat’ (mostly white cells) on top of the
pelletwasremoved,alongwiththesupernatant.Thepellet(mostly
erythrocytes)wasresuspendedin25 mlofresuspensionbufferand
re-centrifuged (2500 g for 20 min). The small amount of buffy
coat on this pellet was removed, along with the supernatant, and
theremainingpellet(erythrocytes)wasthenresuspendedin10 ml
of resuspension buffer and frozen. The combined supernatants
from the two preceding centrifugations were re-centrifuged and
resuspended several times as above (2500 g for 20 min) until no
erythrocytes were evident at the bottom of the pellet, at which
point the ﬁnal pellet of mostly white cells was resuspended and
frozen.
For preparation of serum, fresh blood was left to stand for 4 h,
thencentrifugedat3000 gfor20 min,andthesupernatant(serum)
was decanted and frozen.
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Human experimentation
All human ﬂuid samples were taken with informed consent of
the donors in accordance with the Declaration of Helsinki (2000)
of the World Medical Association and with the relevant ethical
guidelines of the University of Cambridge. The urine sample was
taken from an adult male at 10:30 h, 3 h after a meal consisting
of a bowl of breakfast cereal and a cup of coffee, with the subject
subsequently having free access to water before the sample was
taken.
RESULTS
Characterization of the enzyme and the assay
Using [
3H]InsP6, we established that the Giardia kinase has a
Km of approx. 60 nM (results not shown). We used this enzyme to
makeourown[
3H]InsP7 standardforHPLC.BecausetheGiardia
gene is closely related to InsP6 kinases from other eukaryotes, we
assumed that its product is 5-[PP]InsP5 (see [31] for discussion),
though we have not established its structure. Draskovic et al. [32]
have shown that the mammalian InsP6 kinases are remarkably
speciﬁc for the 5-position such that even on prolonged incubation
they prefer to add a third phosphate there rather than use another
position on the inositol ring. We exposed bona ﬁde 5-[PP]InsP5
synthesized from InsP6 by a mammalian InsP6 kinase [a gift
from Dr S.B. Shears, Inositol Signaling Group, NIEHS (National
Institute of Environmental Health Sciences), Research Triangle
Park, NC, U.S.A.] to the Giardia enzyme for several hours, but
detected no formation of any InsP8, which suggests that Giardia
InsP6 kinase is a 5-kinase too, and that extra phosphorylation of
5-[PP]InsP5 is not a complicating factor in the InsP6 assay.
In the context of this assay, the crucial point is that we always
included a [
3H]InsP7 standard made by the Giardia enzyme in
every HPLC run, and collected and counted 1 min samples indi-
vidually for both isotopes. This leads to a precise co-chromato-
graphy of the
3H-labelled standard and the
32P-labelled product
formed from InsP6 in the cell extract (e.g. Figure 1); any sample
in which this co-chromatography was not absolutely precise was
discarded(exceptforsomeblanks,wherelowlevelsofradioactiv-
ity meant that the correlation was less evident: see below). Note
thatintheFigures,theleft-handaxis()isalwaysthe
3H-labelled
InsP7 standard, and the right-hand axis (), whose scale varies
greatly between Figures (which serves to illustrate the precise
co-chromatography of the two isotopes), is the
32P counts for the
same fractions.
We have discussed elsewhere previously [27], and discounted,
thepossibilityofInsP5 inextractsinterferingsigniﬁcantlywiththe
assay. Brieﬂy, InsP5s are poor substrates for the Giardia enzyme
(see below), and any PPInsP4 products formed elute well before
InsP7 under our HPLC protocol. Any tri-phosphorylated InsP5
[32]wouldbeformedinminuteamountsduringour60 minincub-
ations and also would not precisely co-elute with 5-[PP]InsP5.
High background levels in the region of the HPLC proﬁle where
PPInsP4 elutes prevented us from extensive quantitative analysis
of InsP5s as substrates for the Giardia InsP6 kinase. However, in
one set of experiments with a fresh batch of [γ-
32P]ATP (and con-
sequently lower background) we were able to gain some results
on the approximate efﬁcacy of the six InsP5 isomers (four of
whicharepresentedasracemicpairs)assubstrates.Using300 nM
substrate, the rate of phosphorylation of InsP5 isomers relative to
InsP6 (InsP6 =100%) was 2-OH-InsP5,0 . 5 %; 1/3-OH-InsP5,
3.2%; 4/6-OH-InsP5,3 . 0%, and 5-OH-InsP5 showed no detect-
able phosphorylation over background levels. In parallel experi-
ments, scyllo-inositol hexakisphosphate was phosphorylated at
4.7% o ft h er a t eo fI n s P6.
Figure 1 HPLC proﬁle of a liver InsP6 assay
Three typical proﬁles from three assay tubes are illustrated, with the radioactivity in the InsP7
region (indicated by the peak in [3H]InsP7 elution) shown. Left-hand axis (), [3H]; right-hand
axis (), [32P]. Note the differing scales on the [32P] axes [dpm (d.p.m.)]. (A) Blank incubation
(control), (B)5μl of liver extract, and (C)5μl of liver extract with 10pmol InsP6 added just
before the assay was performed.
We explored whether other compounds present in rat tissue
extracts might interfere with the assay by ‘spiking’ samples
with known quantities of InsP6. We found signiﬁcant levels of
interferencecausedbyfactorspresentintheextracts,whichvaried
considerably between tissues (from a 2–10-fold underestimate of
theInsP6 added),andweattributethistoendogenousATPdiluting
our [γ-
32P]ATP, plus other unknown compounds inhibiting the
enzyme. We tried a number of ‘puriﬁcation’ protocols to separate
InsP6 from these interfering factors, but this only led to losses
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Table 1 InsP6 content of tissues and ﬂuids
Tissues were extracted and assayed as described in the Experimental section. Each assay was
performedintriplicate,andresultsaremeans+ −S.E.M.Foralltissues,atleastoneindependent
assay was performed on another sample, with similar results (results not shown). Note that the
InsP6 concentrationforallsamplesexceptserum,plasmaandurine,isanestimatedintracellular
concentration.
Tissue InsP6 (pmol/mg of protein) InsP6 concentration
Rat liver 39.8+ −0.43 11+ −0.12 μM
Rat brain 194.7+ −25.5 14.5+ −1.9 μM
Rat kidney 55.5+ −7.1 10.9+ −1.4 μM
Rat lung 69.8+ −12.4 15.8+ −2.8 μM
HeLa cells 175+ −16.6 37.6+ −3.5 μM
Slime mould 3645+ −114 352+ −11 μM
Calf serum – <8n M
Human erythrocytes 0.037+ −0.0057 26+ −4.0 nM
Human white cells 43.5+ −6.1 –
Human serum – <0.5 nM
Human plasma – <0.5 nM
Human urine – <5n M
of InsP6, so, in the end, we decided to adopt a protocol where
we performed six assays for any single tissue sample. Three are
aliquotsofthetissueextract,andthreeareidenticalaliquotsspiked
just before the assay with a known amount (usually 10 pmol) of
InsP6. From the difference between these latter spiked samples
and the unspiked samples, we can calculate the d.p.m. of InsP7
formed from the known InsP6, and comparing this with a 10 pmol
standard assayed at the same time quantiﬁes the ‘quenching’
present in each individual tissue sample. This can then be used
to correct the InsP7 formed in the unquenched samples. This is
a rather laborious process (as we also included blank incubated
controls in all experiments), but it does allow us to be conﬁdent
that each sample is quantitatively assayed.
This approach assumes that the quenching is linear with InsP6
concentration (doing a complete standard curve within each
samplewouldbetheonlyrigorouswayofensuringthat).Although
we believe such linearity is indeed likely, some non-linearity
would not seriously compromise the conclusions drawn below
other than to lead to an underestimate of InsP6 in some tissues
listed in Table 1. Whenever possible, we used quantities of cell
extract that contained approximately the same amount of InsP6
as the added spike, which self-evidently helps to ensure linearity
and also simpliﬁes the quantiﬁcation of the degree of quenching.
We tested our extraction protocol by spiking several samples of
rat tissues with [
3H]InsP6 before extraction, and found that we
recovered 80–85% up to the point of adding the enzyme to the
assay. We have corrected all our results for tissue extracts by
assuming 80% recovery.
InsP6 content of rat tissues
Figure1showsatypicalsetofsingleHPLCproﬁlesfromanassay
performed on an extract from rat liver. The combination of the
triplicate samples leads to a level of 4.75 pmol in the sample,
which represents 0.84 mg of wet weight of tissue (0.149 mg
of protein). If we assume an 80% recovery and that there is
0.64 g water/g of tissue (see [33,34] for derivation of this latter
assumption), then the complete assay leads to an estimated intra-
cellular level of 11+ −0.12 μMI n s P6 in the liver.
In a further set of experiments, we then assayed InsP6 levels in
a selection of rat tissues, and the results are shown in Table 1. We
observe no obvious pointers to tissue-speciﬁc functions in these
results, as the concentrations of InsP6 were broadly similar. Per-
haps the most relevant observation in that regard is that compar-
ing the two internal tissues in the body exposed to the highest and
lowest O2 levels (lung and kidney respectively), there is no large
difference. If a principal function of InsP6 in vivo was to act as an
antioxidant [26,35], then one might expect there to be much more
InsP6 in the lung. In fact, the likelihood of InsP6 interacting with
iron ions (the reason for its antioxidant action) inside cells has
been questioned in the light of the discovery that InsP6 probably
exists mostly as a penta-Mg
2+ salt in vivo [36].
Slime moulds
Our calculated concentrations of InsP6 in mammalian tissues are
overall consistent with the indirect calculations derived from
equilibrium labelling of cell cultures with [
3H]inositol (e.g.
[6,37]), but nevertheless we sought an independent validation
of the assay. One organism for which there is already an accurate
massestimationofInsP6 isD.discoideum,whichhasanestimated
intracellular concentration of InsP6 assayed by inorganic phos-
phorous determination as 594 μM [8]. This value is signiﬁcantly
higher than the estimated maximum solubility of the penta-Mg
2+
salt of InsP6 proposed to exist in vivo (approx. 50 μM [38]), and
maybeexplainedbysomeformofcompartmentalizationinacidic
vesicles (see [38] for discussion).
Wethereforeassayedpelletsofaxenalculturesofslimemoulds
for InsP6. The pellets were weighed before extraction, and the
mass levels of InsP6 measured gave an estimated concentration
in the cells of 352+ −11 μM (Table 1). The ﬁgure of 594 μM[ 8 ]
used an assumption of 0.4 g of water/g of pelleted cells, which
corrects to 371 μM if we use the assumption of 0.64 g of water
as determined above. The close agreement between the two sets
of data provides an independent validation of the present assay,
and conﬁrms the really remarkably high InsP6 levels in these
organisms.
HeLa cells
We next assayed InsP6 in conﬂuent cultures of HeLa cells
(Table 1). These have apparently higher levels of InsP6 than rat
tissues; however, the difﬁculty of accurately measuring cellular
wet weight, plus the absence of connective tissue in a cell culture,
limit the interpretability of such comparisons. Nevertheless, these
experiments provided us with an opportunity to investigate the
extent to which mammalian cell lines make all their own InsP6.
InsP6 is reported to be present in human and rat serum or plasma
[17–19], so it is possible that cultured cells derive some or even
all of their InsP6 from the calf serum in the medium in which they
are grown. In this respect, cell cultures could be argued to be a
paradigmforwholeanimalrequirements,astheyarewithinositol
(see[39]andtheDiscussionsection).SowetriedtomeasureInsP6
inthecalfseruminwhichthecellswerecultured,butcoulddetect
none within the limits of the assay. The arguments for these limits
are detailed below when we consider human serum, and, using
this logic, we estimate that there could be no more than 16 pmol
ofInsP6 inthemediumofeach10-cm-diameterdishofcells.Yeta
dish of HeLa cells grown to conﬂuence in that medium contained
1.952+ −0.117 nmol of InsP6. The same medium has been used in
our laboratory to grow numerous other cell lines [e.g. HEK-293
cells (human embryonic kidney cells), COS cells and CHO cells
(Chinese-hamster ovary cells)] for many passages, and so from
these results we conclude that cultured mammalian cells make all
their own InsP6.
Human blood
The absence of detectable InsP6 in calf serum raised the question
of whether this is unique to cows, given that human and rat serum
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are reported to have levels of InsP6 from 30–460 nM (e.g. [19,25]
and see also the Discussion section). So we tested human blood.
We fractionated the blood in two ways. As serum would be a
direct comparison with the calf serum above, for some samples
we let the blood clot and took the supernatant (serum) remaining.
For comparison with measurements of plasma InsP6,a n da l s o
to gain some information about InsP6 in some of the cells in
blood, we also collected blood into citrate, and fractionated it into
erythrocytes, white (buffy coat)cells and platelet-free plasma (we
discarded the platelet fraction).
The results in Table 1 show that we could detect virtually no
InsP6 inerythrocytes(thesmallamountpresentisprobablyaresult
ofwhite-cellcontamination),whichisinitselfaninterestingcom-
parison with nucleated erythrocytes of amphibians and reptiles,
which make high levels of Ins(1,3,4,5,6)P5 [6,40]. For the white
cell (buffy coat) fraction, we only used cellular protein as a
standard, and the results suggest that, as one might expect from
nucleated mammalian cells, human white cells contain InsP6 at a
concentration similar to the rat tissues assayed above (Table 1).
However, in both serum and plasma, we again found no signi-
ﬁcant quantities of InsP6. To illustrate this point, Figure 2 shows
typical HPLC proﬁles from assays on human serum samples
which were (Figure 2C) or were not (Figure 2B) ‘spiked’ with
2.5 pmol of InsP6 before extraction; this extra part of the protocol
wasintroducedtoensurethattherewasnoextractionproblemwith
this particular type of preparation (which has no cells, but a high
protein content). Similar experiments were performed on blood
taken from three individuals and all gave similar results. From
these proﬁles (Figure 2), it is difﬁcult to be accurate as to how
much InsP6 we would have been able to detect. The background
in the
32P channel where [
3H]InsP7 elutes varied between experi-
ments, in general this was lower if the [γ-
32P]ATP was fresh [27],
asthis
32PbackgroundintheHPLCeluateistheultimatelimitation
to the sensitivity of the assay. A further complication is that, in
thatbackground,thereisfrequentlyanapparentminorpeakof
32P
that approximately co-chromatographs with [
3H]InsP7,w h i c hi s
present in both blank and human serum samples (Figures 2A and
2B).Nevertheless,ifwesuggestthat100 d.p.m.abovebackgound
in triplicate samples would have shown up as a distinct and
detectable
32P peak co-incident with [
3H]InsP7 in Figure 2(B),
we can calculate that this would represent no more than 64 fmol
ofInsP6,whichleadsustosuggestthattheplasmasampletypiﬁed
by Figure 2 probably contains less than 0.5 nM InsP6. Moreover,
during plasma preparation, some damage may have occurred to
white cells (or platelets) to release traces of InsP6, and, with
this in mind, we suggest that in vivo blood probably contains no
extracellular InsP6 at all.
Human urine
The other human ﬂuid that has been analysed for InsP6 is urine,
which is reported to contain 1–3 μMI n s P6 (e.g. [20] and see
the Discussion section). We therefore measured InsP6 in a urine
samplefromoneofourblooddonors,againspikingsomesamples
before extraction as well as afterwards to conﬁrm the recovery
of InsP6. The results revealed that there is no detectable InsP6
present.Thereismore‘interference’withtheassayfromunknown
factors present in urine than in plasma or serum, which made the
assay less sensitive. But the assays included 50 μl of samples of
urine spiked with 2.5 pmol InsP6 (ﬁnal concentration of 50 nM)
beforeextraction,andtheseshowedaclearpeakofInsP7 product;
from a similar semi-quantitative logic to that stated above, we can
set a lower limit of InsP6 detection in the samples analysed of
approx. 250 fmol InsP6, the equivalent of 5 nM InsP6 in human
urine.
Figure 2 HPLC proﬁle of a human plasma InsP6 assay
Three typical HPLC proﬁles from three assay tubes are illustrated, with the radioactivity in the
InsP7 region (indicated by the peak in [3H]InsP7 elution) shown. Left-hand axis (), [3H];
right-hand axis (), [32P]. Note the differing scales on the [32P] axes [dpm (d.p.m.)]. (A)B l a n k
incubation(control),(B)extractof100μlofhumanplasma,and(C)extractof100μlofhuman
plasma with 2.5 pmol (25nM ﬁnal concentration) InsP6 added before extraction.
DISCUSSION
The levels of InsP6 that we have measured in mammalian tissues
are of a similar order to those deduced from equilibrium labelling
of cultured cells with [
3H]inositol (e.g. [37], and see [6] for dis-
cussion) and we can conclude that mammalian cells contain tens
of μMI n s P6. If anything, these may be underestimates compro-
mised by a potential non-linearity of the assay when performed
on tissue extracts. Moreover, these calculations assume a uniform
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cytosolic localization, but obviously local concentrations may be
higher. This may be most relevant in the context of well deﬁned
nuclear functions for this inositol phosphate and its more highly
phosphorylated derivatives [11,41–43]. Slime moulds, which
synthesize very high levels of InsP6 very quickly [8], remain
an enigma only deepened by our results.
Crucially, we have shown, as far as we know, for the ﬁrst time,
that HeLa cells in culture (and by implication, all mammalian
cell lines in perpetuity) synthesize all their own InsP6.T h i s
depends, of course, on the cells having sufﬁcient inositol to make
PtdIns(4,5)P2 ([39] and also see the Introduction and Discussion
sections), and we suggest that they probably serve as a paradigm
for humans. The key to this observation is our discovery that
culturedcellshavenosigniﬁcantexternalsourceofInsP6 because
there is none detectable in the calf serum in which we grow them.
This was the most unexpected ﬁnding of our study, and because
of its implications for human diet and health, we went on to
demonstrate, as thoroughly as the assay allows, that there is also
no detectable InsP6 in human serum, plasma (Figure 2) or urine.
These results have important implications for the apparent up-
take of exogenous InsP6 into cells or tissues, and for the proposed
extracellular actions of InsP6 in health and disease. To consider
cells ﬁrst, when radiolabelled InsP6 is added at micromolar
concentrations to mammalian cells in culture it has been reported
to be taken up, but the radiolabel is then found as lower inositol
phosphates or inositol [23,44]. InsP6 binds strongly to Ca
2+,a n d
its solubility limit in the presence of millimolar levels of Ca
2+
is less than 1 μM [36,38]. However, the (insoluble) Ca
2+ salt of
InsP6 has been found to exist naturally, for example, as a compo-
nent of the extracellular coat around the parasitic cestode
Echinococcus granulosus [45] to which it can be transported as
nanometre diameter granules [46]. From these observations, it
seemsthatthemostplausiblemechanismforcellularInsP6 uptake
is endocytotic absorption (possibly as a Ca
2+–InsP6 precipitate),
accompanied by dephosphorylation within the cell.
Consistent with this argument are results from the classic stud-
ies of Eagle et al. [39], in which mammalian cell lines in culture
were shown to require approx. 0.3 μM inositol for growth, and
this requirement could be fully substituted for by inositol mono-
phosphates, or, with a much lower efﬁcacy, by 1 μMI n s P6.I n
this context, we should note that adding InsP6 at much higher (up
to millimolar) concentrations to cell cultures will reduce extra-
cellular Ca
2+ to 1 μM or lower [36], so any subsequent cell
death caused by such high concentrations (e.g. [21,22], and see
[23] for a review) would be simply explained by the very well
establishedrequirementforextracellularCa
2+ inordertomaintain
mammaliancellfunction[47];inshort,thecellsdiebecauseInsP6
removes all the multivalent cations from the culture medium.
Our results have an impact most directly on the issue of the
uptake of InsP6 from the human diet. In a number of studies,
Grases et al. [17–19] have reported that adding InsP6 to the diet,
or the topical application of InsP6-containing creams [20], in-
creases the levels of InsP6 in plasma, urine and tissues. We
have not explored different dietary regimes here, but we would
argue that any such difference is not likely to be crucial. Typical
levels of InsP6 in urine from human subjects kept on an ‘InsP6-
free diet’ are 2–3 μM [20], and in plasma approx. 0.1 μM [19],
whereasrevertingtoan‘InsP6-normaldiet’leadstoapprox.4-fold
increasesintheseparameters.Yetourestimatesofmaximallevels
of InsP6 in human subjects consuming a normal, carnivorous,
cereal-containing diet are respectively (at least) 200 times
(plasma) and 500 times (urine) lower than those reported for
human subjects free of exogenous InsP6 [17–19]. These maxima
are only estimates, and perhaps a more direct demonstration of
the inconsistency between results published previously [17–20]
and ours lies the results for human serum in Figure 2(C) [and
the corresponding results for urine (results not shown)], where
spiking serum or urine with InsP6 concentrations that are still
respectively 4-fold and 40-fold lower than those claimed to be
found in these ﬂuids in InsP6-deprived individuals [17–19] gives
robust signals in our assay that are very much higher than those
from the unspiked samples.
For these reasons, we suggest it is our assay that differs from
other studies, not the diet of the donors. Experiments feeding
radioactive InsP6 to rats showed that it is dephosphorylated
within the gut, and that the radiolabel is subsequently found in
plasma and urine only as inositol and InsP [48], and it has been
shown that microbes in the gut contribute the phytase activity
responsible for this hydrolysis [49]. As the measurement of InsP6
hassofarbeenlargelyperformedby(Dowex)ion-exchangechro-
matography (e.g. [18]) or HPLC [25] of acid extracts, followed
by dephosphorylation of the fractions with phytase and then
determination of myo-inositol (with a scyllo-inositol standard)
by MS, it is conceivable that, as also suggested by Shears [7], the
presence of high concentrations of anions (including multivalent
anions such as ATP) in the tissue extracts might compromise
inositol phosphate separation protocols characterized in their
absence.
Thus although our assay is not designed for the quantiﬁcation
of lower inositol phosphates, we can combine our results with the
literature published previously [48,49] to suggest that InsP6 is not
absorbed directly from the diet, but rather is dephosphorylated
before it is taken up; note that the results of Wise and Gilburt
[49] conﬁrm that in the absence of any hydrolysis by gut ﬂora,
there is no signiﬁcant InsP6 absorption. The inositol and InsP
generated by dephosphorylation will of course not be without
effect: inositol is synthesized de novo by animals (from glucose
6-phosphate via Ins3P, see [6]), but most mammalian tissues do
not produce enough of it, and so inositol is a vitamin (vitamin Bh)
for which a signiﬁcant dietary source is InsP6 from cereals. Free
levelsofinositolarehighinmanymammaliancells(e.g.[50]),but
theKm forPtdInssynthetaseisalsohigh[51],soifraisinglevelsof
dietary InsP6 leads to increases in the availability of inositol and
InsP to tissues, a mass-action effect might be expected on PtdIns
synthetase, perhaps leading to increases in steady-state inositol
lipid and phosphate levels.
So, if the conclusion of the present study is that we (humans)
do indeed make all our InsP6 (by the route described in the
Introduction), and that we derive none directly from our diet,
what effect(s) will exogenous InsP6, something claimed to be of
signiﬁcant medical beneﬁt [23,24], cause? From the arguments in
the preceding paragraph, increases may occur in cellular inositide
levels (including InsP6), but this effect would be indirect, and
high dietary inositol or InsP would be expected to do the same
thing. Any speciﬁc and direct actions of exogenous InsP6 will
be conﬁned to its place of application. Such direct actions would
stem from its ability to bind all multivalent cations with high
afﬁnity [36,38]. Binding Fe
3+ gives InsP6 unique and potent
antioxidant properties [26,35], so it is likely that dietary InsP6
will alter oxidative processes within the gut. This, and its general
chelation of cations (e.g. Fe
3+,Z n
2+ and Ca
2+) to restrict their
uptake,probablyunderliethereportedeffectsofInsP6 invivo(e.g.
[23,24]). These ion-binding actions of InsP6 can have undesirable
consequences, either environmental, such as depleting Fe
3+ or
Zn
2+ from some soils [52], or physiological, by InsP6 removing
these same essential cations from the human diet to a degree
that can be deleterious, depending on the nutritional status of the
individual [53–56].
However, a major thrust of many of the arguments for the
beneﬁts of InsP6 to humans [23,24] stems from a combination of
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two factors: (a) the killing of tumour-cell cultures by applying to
them high extracellular levels of InsP6, which, we argue above,
is of questionable physiological relevance; and (b) an assumption
that exogenous InsP6 is taken up directly to form a signiﬁcant
extracellular InsP6 pool, which bathes some or all our cells and
which, because of its unique chemistry, can in turn inﬂuence their
physiologyorpathology.Itisthislatterassumptionthattheresults
in the present study suggest requires reconsideration.
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